Bristol Myers Squibb deploys Anthropic Claude to 30,000 staff for drug discovery

TL;DR:

  • Bristol Myers Squibb said on Wednesday it will make Anthropic’s Claude AI model available to more than 30,000 employees, alongside Anthropic’s coding tool Claude Code, to accelerate drug discovery, development and delivery.
  • The pharmaceutical company will evaluate Claude’s use across research, drug development, manufacturing and commercial and medical affairs — a wider deployment than the chatbot pilots most large enterprises have run to date.
  • Chief digital and technology officer Greg Meyers said the goal is unlocking value “still trapped behind decades of data silos”, positioning the rollout as an attempt to move past the productivity-tool framing that has limited earlier enterprise AI investments.

The Bristol Myers deal lands the same day Anthropic told investors it is closing in on its first quarterly operating profit, and follows Eli Lilly’s expanded partnership with Nvidia. Big Pharma is now committing to AI at a scale and depth that goes well beyond ChatGPT-style coding assistants, with each major announcement bringing the question of where regulated industries draw the line between AI-assisted research and AI-derived results closer to the foreground.

A regulated-sector commitment that matters for the UK pharma cluster

Drug R&D is a slow, expensive industry with regulators on every step — the MHRA in the UK, the FDA in the US, the EMA in Europe — and a long history of being cautious about new tools touching submission-grade work. A 30,000-employee Claude rollout into a sector that conservative is a substantive bet, not a press release. McKinsey estimated last year that agentic AI could lift clinical-development productivity by 35-45% over five years; the Bristol Myers programme will become one of the largest live tests of whether that estimate survives contact with regulated pharma reality.

For the UK life-sciences sector — anchored around Cambridge, Stevenage and the Oxford-Cambridge arc — the read-through matters. AstraZeneca, GSK and the rest of the UK pharma cluster are watching how a US peer scales Claude across a regulated workflow. UK-based contract research organisations and biotech spin-outs serving Big Pharma will see the procurement consequences before the science ones: shorter expected turnaround times, more AI-derived deliverables, and new audit-trail expectations that the MHRA has not yet detailed.

Looking forward

Bristol Myers said it will evaluate the deployment across research, drug development, manufacturing and other commercial and medical affairs — the breadth of scope is itself a signal. Watch for the first regulated-submission disclosures that flag AI-assisted content, the MHRA and FDA guidance updates likely to follow, and whether the Bristol Myers/Anthropic model becomes the template UK and EU peers borrow rather than build their own. The McKinsey 35-45% productivity-uplift claim will face its first reality check in the company’s clinical pipeline disclosures over the next year — alongside the Ada Lovelace Institute’s wider warning that public-sector AI productivity estimates need much sharper scrutiny.

Share this article